2-溴-4-甲基-6-硝基苯胺 | 827-24-7

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-4-甲基-6-硝基苯胺
• 英文名称: 2-bromo-4-methyl-6-nitroaniline
• 英文别名: 2-bromo-4-methyl-6-nitrobenzenamine
• CAS: 827-24-7
• 化学式: C₇H₇BrN₂O₂
• mdl: MFCD00209452
• 分子量: 231.049
• InChiKey: VFPKZASVVCBVMG-UHFFFAOYSA-N

物化性质

• 熔点：
  64-66
• 沸点：
  329.1±37.0 °C(Predicted)
• 密度：
  1.698±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2921430090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-4-methyl-6-nitroaniline
Synonyms: 2-Bromo-4-methyl-6-nitrobenzenamine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-4-methyl-6-nitroaniline
CAS number: 827-24-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H7BrN2O2
Molecular weight: 231.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-4-甲基-6-硝基苯胺 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 sodium nitrite 作用下， 以 四氯化碳 、 水 、 溶剂黄146 为溶剂， 反应 66.0h， 生成 1-溴-3-(溴甲基)-5-硝基苯
  参考文献：
  名称：

  Design, synthesis and structure–activity relationships of novel phenylalanine-based amino acids as kainate receptors ligands

  摘要：

  A new series of carboxyaryl-substituted phenylalanines was designed, synthesized and pharmacologically characterized in vitro at native rat ionotropic glutamate receptors as well as at cloned homomeric kainate receptors GluK1-GluK3. Among them, six compounds bound to GluK1 receptor subtypes with reasonable affinity (K-1 values in the range of 4.9-7.5 mu M). A structure-activity relationship (SAR) for the obtained series, focused mainly on the pharmacological effect of structural modifications in the 4- and 5-position of the phenylalanine ring, was established. To illustrate the results, molecular docking of the synthesized series to the X-ray structure of GluK1 ligand binding core was performed. The influence of individual substituents at the phenylalanine ring for both the affinity and selectivity at AMPA, GluK1 and GluK3 receptors was analyzed, giving directions for future studies. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.09.075
• 作为产物：
  描述：

  2'-溴-4'-甲基乙酰苯胺 在 硝酸 作用下， 生成 2-溴-4-甲基-6-硝基苯胺
  参考文献：
  名称：

  Wroblewski, Justus Liebigs Annalen der Chemie, 1878, vol. 192, p. 203

  摘要：

  DOI：

文献信息

• Modular metal-free catalytic radical annulation of cyclic diaryliodoniums to access π-extended arenes
  作者：Daqian Zhu、Hui Peng、Yameng Sun、Zhouming Wu、Yun Wang、Bingling Luo、Tiantian Yu、Yumin Hu、Peng Huang、Shijun Wen

  DOI：10.1039/d0gc04183a

  日期：——

  Tert-butylamine-catalyzed free radical annulations with cyclic diaryliodoniums occur in environmentally friendly ethyl acetate and do not require transition metal, providing diversified polycyclic aromatic hydrocarbons by modulating substituents.

  叔丁胺催化的自由基环化反应与环状二芳基碘嗡盐在环保的乙酸乙酯中进行，无需过渡金属，通过调节取代基可提供多样化的多环芳烃。

• [EN] BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS PAR HÉTÉROARYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018013774A1

  公开（公告）日：2018-01-18

  Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

  公开了公式(I)至(VIII)的化合物：(I) (II) (III) (IV) (V) (VI) (VII) (VIII)；或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中R3是与0至3个R3a取代的双环杂芳基团；且R1、R2、R3a、R4和n在此定义。还公开了使用这些化合物作为PAR4抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物用于抑制或预防血小板聚集，用于治疗血栓栓塞障碍或作为血栓栓塞障碍的初级预防。
• [EN] TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES DE QUINOLÉINE ET D'AZAQUINOLINE À SUBSTITUTION HÉTÉROARYLE INHIBITEURS DE PAR4
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018013776A1

  公开（公告）日：2018-01-18

  Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

  揭示了化合物的结构式（I）至（VIII）：（I）（II）（III）（IV）（V）（VI）（VII）（VIII）或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中R3是一个三环杂芳基，其上取代有R3a和零至2个R3b；R1、R2、R3a、R3b、R4和n在此有定义。还揭示了将这些化合物用作PAR4抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在抑制或预防血小板聚集方面很有用，并且可用于治疗血栓栓塞性疾病或血栓栓塞性疾病的初级预防。
• Relayed Regioselective Alkynylation/Olefination of Unsymmetrical Cyclic Diaryliodonium Species Catalyzed by Cu and Pd: Affording Fluorescent Cytotoxic Benzoxazoles
  作者：Daqian Zhu、Panpan Liu、Wenhua Lu、Haiwen Wang、Bingling Luo、Yumin Hu、Peng Huang、Shijun Wen

  DOI：10.1002/chem.201503791

  日期：2015.12.21

  Although cyclic diaryliodonium species have the potential to act as valuable synthons for cascade transformations, they still remain largely unexplored. The regioselectivity associated with unsymmetrical cyclic diaryliodonium species has previously been known to pose a challenge. A regioselective relayed alkynylation and olefination of unsymmetrical cyclic diaryliodonium species has been achieved by

  尽管环状二芳基碘鎓物种具有充当级联转化的有价值的合成子的潜力，但它们仍然很大程度上未被开发。先前已经知道与不对称环状二芳基碘鎓物种有关的区域选择性提出了挑战。通过安装直接的氨基基团，实现了不对称环状二芳基碘鎓物种的区域选择性中继炔基化和烯化。延迟这些中继的转化，直到形成恶唑环，从而提供一系列独特的荧光苯并恶唑。而且，这些合成的苯并恶唑中的一些对恶性癌细胞表现出明显的抑制活性。进一步的共聚焦显像表明，苯并恶唑靶向细胞核。
• Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold
  作者：Shangde Liu、Duo Yuan、Shanshan Li、Roujie Xie、Yi Kong、Xiong Zhu

  DOI：10.1016/j.ejmech.2021.113764

  日期：2021.12

  date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly

  蛋白酶激活受体 4 (PAR4) 是抗血小板治疗的重要靶点，可降低中风心脏病发作和血栓并发症的风险。PAR4 拮抗剂通过作用于血小板聚集的晚期扩散阶段，可以防止有害和稳定的血栓生长，同时保留初始血栓形成，并可能为其他抗血小板药物提供更安全的替代品。迄今为止，只有两种 PAR4 拮抗剂BMS-986120和BMS-986141已进入血栓形成的临床试验。因此，非常需要开发具有新化学型的强效和选择性PAR4拮抗剂。在本研究中，我们探讨了 quinazolin-4(3 H)-基于 PAR4 的拮抗剂，从其 IDT 类似物开始。通过反复的结构优化，我们开发了一系列对人血小板具有纳摩尔效力的高选择性 PAR4 拮抗剂。其中，13和30g具有 8-苯并[ d ]噻唑-2-基-取代的 quinazolin-4(3 H )-one 结构，显示出最佳活性（h. PAR4-AP PRP IC 50  = 19.6